| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |